Want to see SINT full AI Analyst Report?
Top Page
Sintx Technologies
(NASDAQ:SINT)
Select Model
Select Model
Rating:51Neutral
Price Target:
$2.00
▲(26.58% Upside)
Action:Reiterated
Date:10/10/26
The score is held back primarily by weak financial performance driven by ongoing losses and significant cash burn. Offsetting this, technical momentum has improved and recent updates point to better near-term revenue traction (including preliminary Q3 outperformance) and operational progress, though liquidity/financing needs and execution uncertainty remain key risks.
Positive Factors
Industrial revenue traction
The sharp increase in industrial ceramics revenue and initial shipment conversion demonstrate emerging commercial traction beyond development-stage activity. If sustained, this customer demand can broaden the revenue base, support manufacturing scale, and help fund continued investment in medical technologies.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow means the business is not yet funding its operations internally. Continued burn can consume available liquidity, restrict investment flexibility, and require additional financing before commercial growth translates into self-sustaining cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Industrial revenue traction
The sharp increase in industrial ceramics revenue and initial shipment conversion demonstrate emerging commercial traction beyond development-stage activity. If sustained, this customer demand can broaden the revenue base, support manufacturing scale, and help fund continued investment in medical technologies.
Read all positive factors
Sintx Technologies (SINT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.06M
Dividend YieldN/A
Average Volume (3M)62.77K
Price to Earnings (P/E)―
Beta (1Y)2.24
Revenue Growth-28.53%
EPS Growth47.55%
CountryUS
Employees32
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,664,534
10 Day Avg. Volume137,950
30 Day Avg. Volume62,775
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.66
Price to Sales (P/S)10.52
P/FCF Ratio-1.22
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue6.25
Enterprise Value/Gross Profit-134.82
Enterprise Value/Ebitda-0.81
Forecast
1Y Price Target
$9.50Price Target Upside501.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sintx Technologies Business Overview & Revenue Model
Company Description
Sintx Technologies, Inc. is an advanced materials enterprise dedicated to researching, developing, and commercializing medical devices crafted from silicon nitride. These innovative products serve biomedical, industrial, and antipathogenic uses, p...
How the Company Makes Money
Sintx Technologies makes money primarily through the commercialization of its silicon nitride materials technology, where available revenue sources may include (a) licensing its intellectual property and know-how to third parties, (b) royalties or...
Sintx Technologies Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.38M | 1.02M | 1.25M | 2.63M | 601.00K | 606.00K |
| Gross Profit | -64.00K | -201.00K | 435.00K | 1.84M | 336.00K | 157.00K |
| EBITDA | -10.62M | -9.65M | -9.61M | -6.60M | -11.06M | -8.63M |
| Net Income | -18.00M | -17.08M | -11.02M | -8.26M | -12.04M | -9.31M |
Balance Sheet | ||||||
| Total Assets | 10.43M | 9.51M | 9.41M | 15.37M | 15.77M | 21.84M |
| Cash, Cash Equivalents and Short-Term Investments | 3.59M | 4.14M | 3.60M | 3.34M | 6.25M | 14.27M |
| Total Debt | 3.05M | 3.25M | 4.03M | 4.76M | 3.63M | 2.91M |
| Total Liabilities | 5.60M | 6.58M | 5.52M | 6.59M | 10.07M | 4.64M |
| Stockholders Equity | 4.83M | 2.93M | 3.89M | 8.77M | 5.70M | 17.20M |
Cash Flow | ||||||
| Free Cash Flow | -10.34M | -8.76M | -9.33M | -14.64M | -11.67M | -13.87M |
| Operating Cash Flow | -10.12M | -8.57M | -8.64M | -14.12M | -10.26M | -10.13M |
| Investing Cash Flow | 533.00K | 913.00K | -194.00K | -501.00K | -1.10M | -1.66M |
| Financing Cash Flow | 8.86M | 8.20M | 9.09M | 11.71M | 3.34M | 705.00K |
Sintx Technologies Technical Analysis
Positive
1.58
Price Trends
1.76
Positive
1.84
Positive
2.38
Negative
Market Momentum
0.13
Negative
62.61
Neutral
44.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SINT, the sentiment is Positive. The current price of 1.58 is below the 20-day moving average (MA) of 1.95, below the 50-day MA of 1.76, and below the 200-day MA of 2.38, indicating a neutral trend. The MACD of 0.13 indicates Negative momentum. The RSI at 62.61 is Neutral, neither overbought nor oversold. The STOCH value of 44.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SINT.
Sintx Technologies Risk Analysis
Sintx Technologies disclosed 38 risk factors in its most recent earnings report. Sintx Technologies reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sintx Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $113.18B | 21.63 | 10.60% | 3.23% | 9.77% | 12.28% | |
73 Outperform | $106.38B | 28.50 | 16.36% | 1.27% | 8.48% | 27.36% | |
71 Outperform | $17.00B | 21.58 | 6.36% | 1.08% | 8.62% | 0.09% | |
55 Neutral | $373.52M | -5.97 | -14.05% | ― | 2.99% | 51.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $14.06M | -0.39 | -565.55% | ― | -28.53% | 47.55% | |
44 Neutral | $1.05B | -145.77 | -0.69% | ― | 1.60% | 98.56% |
* Healthcare Sector Average
SINT
Sintx Technologies
2.11
-1.94
-47.90%
IART
Integra Lifesciences
13.44
-0.18
-1.32%
MDT
Medtronic
88.48
-4.03
-4.36%
OFIX
Orthofix Medical
9.17
-5.33
-36.76%
SYK
Stryker
277.33
-83.59
-23.16%
ZBH
Zimmer Biomet Holdings
89.14
-4.94
-5.25%
Sintx Technologies Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Sintx Technologies Completes Class B Warrant Exercises
Positive
Oct 9, 2026
On October 1, 2026, SINTX Technologies, Inc. delivered call notices to holders of its outstanding Class B Common Stock Purchase Warrants, with the call period ending on October 8, 2026. During this window, the company received gross proceeds of ab...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Sintx Technologies Reports Surging Preliminary Third-Quarter Revenue
Positive
Oct 1, 2026
In a press release dated October 1, 2026, SINTX Technologies reported preliminary, unaudited third-quarter 2026 revenue of $2.2 million, far above prior guidance of $0.9 million to $1.1 million and representing roughly 380% growth from the second ...
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
SINTX Regains Nasdaq Compliance, Supporting Growth Initiatives
Positive
Aug 13, 2026
On August 12, 2026, SINTX Technologies received notice from Nasdaq’s Listing Qualifications Staff that it had regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement of $2.5 million under Lis...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Sintx Technologies Advances Commercialization and Strengthens Financial Position
Positive
Aug 11, 2026
During the first half of 2026, SINTX advanced commercialization of its SiNAPTIC Foot Ankle Implant and Osteotomy Wedge Systems following FDA clearance in October 2025, building a U.S. network of twelve independent orthopedic distributors. Managem...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.